Abstract
Objectives Since February 2020, COVID-19 has spread rapidly to more than 200 countries in the world. During the pandemic, local governments in China implemented different interventions to efficiently control the spread of the epidemic. Characterizing transmission of COVID-19 under some typical interventions is to help countries develop appropriate interventions.
Methods We established compartmental model that allowed the number of infected and infectious to be unknown and the effective reproduction number to change over time, thus the effects of policies could be reasonably reflected and estimated. By using the epidemic data of three representative cities of China (Wuhan, Wenzhou and Shenzhen), we migrated the estimated policy modes to other countries.
Results The smallest expected cumulative confirmed cases under different interventions would be 5936 with 95% CI (5012,6966) for South Korea, 146012 with 95% CI (140504, 154264) for Italy, and 400642 with 95% CI (390331,409431) for the United States until May 31, 2020, respectively.
Conclusions Based on the simulation of epidemic in South Korea, Italy and the United States, it is reasonable that South Korea and Italy continue to maintain their current policies, while the implementation of interventions of Wenzhou may significantly decrease the magnitude of the outbreak of COVID-19 for the United States.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
We would like to thank all individuals who are collecting epidemiological data of the COVID-19 outbreak around the world. This study was partly supported by the National Key Research and Development Program of China (Grant No. 2018YFC1315400), the National Natural Science Foundation of China (Grant No. 11771462, and Grant No. 71991474), the Key Research and Development Program of Guangdong, China (Grant No. 2019B020228001), and the Fundamental Research Funds for the Central Universities (Grant No. 19lgpy236)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The epidemic data were extracted for Wuhan, Wenzhou, and Shenzhen from the Chinese Center for Disease Control and Prevention (China CDC) (National Health Commission of the People’s Republic of China, 2020), and the data for South Korea, Italy and the United States were downloaded through April 23, 2020 from COVID-19 Knowledge & Data Hub (Sciences, 2020).
